Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)
Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label Phase II study evaluating the safety and efficacy of
intravitreally administered ranibizumab 0.5mg in subjects with Proliferative Diabetic
Retinopathy experiencing post- Panretinal Photocoagulation (PRP) macular edema.